Formylated Peptide Receptor-1 (FPR1) mediated gut inflammation as a therapeutic target in Inflammatory Bowel Disease
McAllister MJ, Hall R, Whelan RJ, Fischer LJ, Chuah CS, Cartlidge PD, Drury B, Rutherford DG, Duffin RM, Cartwright JA, Dorward DA, Rossi AG, Ho GT.
Crohn’s & Colitis 360 2024
Circulating Cell-Free DNA in Inflammatory Bowel Disease: Liquid Biopsies with Mechanistic and Translational Implications.
Chuah CS, Fischer L, Ho GT.
Faculty Reviews 2023
Neutrophil-dependent Mitochondrial DNA Release Associated With Extracellular Trap Formation in Inflammatory Bowel Disease.
Drury B, Chuah CS, Hall R, Hardisty GR, Rossi AG, Ho GT.
Gastro Hep Advances 2023
Letter: non-selective beta-blockers in cirrhosis—effect beyond portal hypertension. Authors’ reply.
Dunne P, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead JA, Smith LA, Gaya DR, Forrest EH, Stanley AJ.
Alimentary Pharmacology & Therapeutics 2022
Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial.
Dunne P, Young D, Chuah CS, Hayes PC, Tripathi D, Leithead JA, Smith LA, Gaya DR, Forrest EH, Stanley AJ.
Alimentary Pharmacology & Therapeutics 2022
Intestinal protein characterisation of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in inflammatory bowel disease and fatal COVID-19 infection.
McAllister MJ, Kirkwood K, Chuah CS, Thompson EJ, Cartwright JA, Russell CD, Dorward DA, Lucas CD, Ho GT.
Inflammation 2021
Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study.
McDowell H, Chuah CS, Tripathi D, Stanley AJ, Forrest EH, Hayes PC.
Alimentary Pharmacology & Therapeutics 2021
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn’s disease: the Scottish ustekinumab cohort.
Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam WL, Saunders J, Kelly C, Gaya D, Jafferbhoy H, MacDonald JC, Seenan JP, Mowat C, Naismith G, Potts LF, Sutherland DI, Watts D, Arnott I, Bain G, Jones G, Lees CW.
Journal of Gastroenterology and Hepatology 2020
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease.
Plevris N, Fulforth J, Lyons M, Siakavellas S, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones GR, Lees CW.
Clinical Gastroenterology and Hepatology 2020
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N, Chuah CS, Allen RM, Lees CW et al.
Journal of Crohn’s and Colitis 2019
Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease.
Plevris N, Jenkinson PW, Chuah CS, Lyons M, Merchant LM, Pattenden R, Arnott ID, Jones GR, Lees CW.
Frontline Gastroenterology 2019
Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn’s Disease Are Associated With Biologic Remission.
Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW.
Inflammatory Bowel Diseases 2019
Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes.
Plevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW.
Digestive Disease and Sciences 2019
Case of steroid-resistant Crohn’s-associated bronchiolitis in the setting of quiescent gastrointestinal disease treated with infliximab.
Chuah CS, Noble C, Leitch A.
BMJ Case Reports 2018
Hydrogen ion concentration and coronary artery bypass graft surgery with and without cardiopulmonary bypass.
CS Chuah, R Kirkbride, P Alston, J Irons
Journal of Cardiothoracic Surgery 2013